Screening for hepatocellular carcinoma: why, when, how?

Hepatocellular carcinoma (HCC) is a major public health concern in many areas of the world, and its incidence is increasing in the United States and other countries. Screening for HCC in patients with cirrhosis has been advocated to identify those with small lesions who would benefit from transplant...

Full description

Saved in:
Bibliographic Details
Published in:Current gastroenterology reports 2003, Vol.5 (1), p.57-62
Main Author: Arguedas, Miguel R
Format: Article
Language:English
Subjects:
alpha-Fetoproteins - analysis
Biomarkers - analysis
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - economics
Cost-Benefit Analysis
Humans
Liver cancer
Liver Neoplasms - diagnosis
Liver Neoplasms - economics
Magnetic Resonance Imaging
Sensitivity and Specificity
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is a major public health concern in many areas of the world, and its incidence is increasing in the United States and other countries. Screening for HCC in patients with cirrhosis has been advocated to identify those with small lesions who would benefit from transplantation or surgical resection. Despite these recommendations, several issues regarding screening remain controversial. No randomized, controlled trials have confirmed that surveillance for HCC reduces disease-specific mortality. In addition, the most appropriate screening test and optimal screening interval have not yet been defined. Clearly, these unresolved questions have a major impact on the cost-effectiveness of a screening program either at the population or the clinic level. A few studies, however, have suggested that screening may be cost-effective because a minor survival benefit could result in a cost that is acceptable to decision makers.
ISSN:1522-8037
1534-312X
DOI:10.1007/s11894-003-0010-1